New study aims to tame cholesterol side effect of lung cancer drug

NCT ID NCT07674524

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study looks at the best way to manage high cholesterol caused by the targeted therapy lorlatinib in people with advanced ALK-positive non-small cell lung cancer. Some participants receive standard cholesterol-lowering drugs, while others get a more intensive combination. The goal is to find a strategy that controls cholesterol without disrupting cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Rosuvastatin, Ezetimibe, Evolocumab
What this could lead to
If successful, this could establish a standard way to manage cholesterol side effects from lorlatinib, helping patients stay on their cancer treatment longer.
What could go wrong
This is a relatively small study focused on managing a side effect, not curing cancer. The intensive drug combination may cause additional side effects or not be widely adopted.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALK GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.